Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Expression and prognostic role of syndecan-2 in prostate cancer

Prostate Cancer and Prostatic Diseases volume 13, pages 78–82 (2010)Cite this article

Abstract

Syndecans are a four-member family of transmembrane heparan sulphate proteoglycans that have different functions in cell signalling, adhesion, cytoskeleton organization, migration, proliferation, and angiogenesis. Several studies investigated the role of syndecan-2 (SDC2) in different carcinomas; however, only one being focused on SDC2 in prostate cancer. SDC2 expression and relationship with established prognostic features were assessed in a cohort of 86 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. SDC2 expression was present in the majority of prostate cancers and absent in only 11.6% of cases. SDC2 expression was also recorded in cells of prostatic intraepithelial neoplasia, whereas normal prostatic epithelial tissue and stroma did not express SDC2. SDC2 overexpression in prostate cancer was significantly associated with established features indicative of worse prognosis such as higher preoperative PSA (P=0.011), higher Gleason score (P<0.001), positive surgical margins (P<0.003), and extraprostatic extension of disease (P<0.003). Moreover, expression of SDC2 was also associated with biochemical disease progression on univariate analysis (P<0.001). Study results supported the potential role of SDC2 in prostatic carcinogenesis and cancer progression. Moreover, SDC2 could serve as an additional prognostic marker that might help in further stratifying the risk of disease progression in patients with prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Rapraeger AC . Syndecan-regulated receptor signaling. J Cell Biol 2000; 149: 995–998.

    Article  CAS  Google Scholar 

  2. Essner JJ, Chen E, Ekker SC . Syndecan-2. Int J Biochem Cell Biol 2006; 38: 152–156.

    Article  CAS  Google Scholar 

  3. Simons M, Horovitz A . Syndecan-4-mediated signaling. Cell Signal 2001; 13: 855–866.

    Article  CAS  Google Scholar 

  4. Woods A, Couchman JR . Syndecan-4 and focal adhesion function. Curr Opin Cell Biol 2001; 13: 578–583.

    Article  CAS  Google Scholar 

  5. Choi S, Lee E, Kwon S, Park H, Yi JY, Kim S et al. Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4. J Biol Chem 2005; 280: 42573–42579.

    Article  CAS  Google Scholar 

  6. Noguer O, Villena J, Lorita J, Vilaro S, Reina M . Syndecan-2 downregulation impairs angiogenesis in human microvascular endothelial cells. Exp Cell Res 2009; 315: 795–808.

    Article  CAS  Google Scholar 

  7. Marynen P, Zhang J, Cassiman JJ, Van den Berghe H, David G . Partial primary structure of the 48- and 90-kilodalton core proteins of cell surface-associated heparan sulfate proteoglycans of lung fibroblasts. Prediction of an integral membrane domain and evidence for multiple distinct core proteins at the cell surface of human lung fibroblasts. J Biol Chem 1989; 264: 7017–7024.

    CAS  PubMed  Google Scholar 

  8. Tkachenko E, Rhodes JM, Simons M . Syndecans: new kids on the signaling block. Circ Res 2005; 96: 488–500.

    Article  CAS  Google Scholar 

  9. Han I, Park H, Oh ES . New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J Mol Histol 2004; 35: 319–326.

    Article  CAS  Google Scholar 

  10. Huang JW, Chen CL, Chuang NN . P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005; 329: 855–862.

    Article  CAS  Google Scholar 

  11. Kim Y, Park H, Lim Y, Han I, Kwon HJ, Woods A et al. Decreased syndecan-2 expression correlates with trichostatin-A-induced morphological changes and reduced tumorigenic activity in colon carcinoma cells. Oncogene 2003; 22: 826–830.

    Article  CAS  Google Scholar 

  12. Choi S, Kim Y, Park H, Han IO, Chung E, Lee SY et al. Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2. Biochem Biophys Res Commun 2009; 384: 231–235.

    Article  CAS  Google Scholar 

  13. Gulyas M, Hjerpe A . Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003; 199: 479–487.

    Article  CAS  Google Scholar 

  14. Park H, Kim Y, Lim Y, Han I, Oh ES . Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002; 277: 29730–29736.

    Article  CAS  Google Scholar 

  15. Huang X, Xiao DW, Xu LY, Zhong HJ, Liao LD, Xie ZF et al. Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma. Oncol Rep 2009; 21: 1123–1239.

    CAS  PubMed  Google Scholar 

  16. Contreras HR, Ledezma RA, Vergara J, Cifuentes F, Barra C, Cabello P et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol 2009. May 16. [Epub ahead of print], PMID:19450993, doi:10.1016/j.urolonc.2009.03.018.

  17. Sobin LH, Wittekind C (eds) International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 5th edn. Wiley Liss: New York, USA, 1997. pp 170–173.

    Google Scholar 

  18. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003; 55: 20–29.

    Article  Google Scholar 

  19. Shariat SF, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI et al. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int 2008; 101: 232–237.

    Article  Google Scholar 

  20. Kiviniemi J, Kallajoki M, Kujala I, Matikainen MT, Alanen K, Jalkanen M et al. Altered expression of syndecan-1 in prostate cancer. APMIS 2004; 112: 89–97.

    Article  CAS  Google Scholar 

  21. Chen D, Adenekan B, Chen L, Vaughan ED, Gerald W, Feng Z et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004; 63: 402–407.

    Article  Google Scholar 

  22. Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Konishi N . Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci 2009. April 21. [Epub ahead of print], PMID:19432893, doi:10.1111/j.1349-7006.2009.01174.

Download references

Author information

Authors and Affiliations

  1. University Department of Urology, Zagreb, Croatia

    A Popović, B Spajić & G Štimac

  2. University Department of Pathology, Sestre milosrdnice University Hospital, Zagreb, Croatia

    A Demirović, B Krušlin & D Tomas

  3. School of Medicine, University of Zagreb, Zagreb, Croatia

    B Krušlin & D Tomas

Authors
  1. A Popović
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Demirović
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Spajić
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Štimac
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Krušlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Tomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Tomas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Popović, A., Demirović, A., Spajić, B. et al. Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis 13, 78–82 (2010). https://doi.org/10.1038/pcan.2009.43

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.43

Keywords

This article is cited by

Search

Advanced search

Quick links